Skip to main content
Premium Trial:

Request an Annual Quote

Harvard, Dana-Farber License Screening Platform to Acetylon

By a GenomeWeb staff reporter

NEW YORK (Genomeweb News) – Harvard University and the Dana-Farber Cancer Institute today said that they have licensed exclusive rights to a high-throughput screening and lead optimization platform for histone deactylase (HDAC) inhibitor compounds to Acetylon Pharmaceuticals.

The partners did not provide details on the screening and optimization platform.

Harvard and Dana-Farber received equity from Acetylon and also will receive downstream royalty and milestone payments, under terms of the licensing agreement.

Boston-based Acetylon was founded on core technology developed at Harvard and Dana-Farber. The firm is developing drug candidates based on next-generation Class II-selective HDAC inhibitors.

The Scan

And Back

The New York Times reports that missing SARS-CoV-2 genome sequences are back in a different database.

Lacks Family Hires Attorney

A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports.

For the Unknown

The Associated Press reports that family members are calling on the US military to use new DNA analysis techniques to identify unknown sailors and Marines who were on the USS Arizona.

PLOS Papers on Congenital Heart Disease, COVID-19 Infection Host MicroRNAs, Multiple Malformation Mutations

In PLOS this week: new genes linked to congenital heart disease, microRNAs with altered expression in COVID-19, and more.